Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Patient-derived xenografts of central nervous system metastasis reveal expansion of aggressive minor clones.

Tew BY, Legendre C, Schroeder MA, Triche T, Gooden GC, Huang Y, Butry L, Ma DJ, Johnson K, Martinez RA, Pierobon M, Petricoin EF, O'Shaughnessy J, Osborne C, Tapia C, Buckley DN, Glen J, Bernstein M, Sarkaria JN, Toms SA, Salhia B.

Neuro Oncol. 2019 Aug 21. pii: noz137. doi: 10.1093/neuonc/noz137. [Epub ahead of print]

PMID:
31433055
2.

Central nervous system involvement in children and adolescents with rhabdomyosarcoma. A report from the AIEOP Soft Tissue Sarcoma Committee.

Pierobon M, Ferrari A, Scarzello G, Tamburini A, Quaglietta L, Ruggiero A, Milano GM, Zin A, Bisogno G.

Neurooncol Pract. 2018 Nov;5(4):241-245. doi: 10.1093/nop/npy007. Epub 2018 Mar 27.

PMID:
31386009
3.

Endogenous Gastrin Collaborates With Mutant KRAS in Pancreatic Carcinogenesis.

Nadella S, Burks J, Huber M, Wang J, Cao H, Kallakury B, Tucker RD, Boca SM, Jermusyck A, Collins I, Vietsch EE, Pierobon M, Hodge KA, Cui W, Amundadottir LT, Petricoin E 3rd, Shivapurkar N, Smith JP.

Pancreas. 2019 Aug;48(7):894-903. doi: 10.1097/MPA.0000000000001360.

PMID:
31268978
4.

Utilization of Proteomic Technologies for Precision Oncology Applications.

Pierobon M, Wulfkuhle J, Liotta LA, Petricoin Iii EF.

Cancer Treat Res. 2019;178:171-187. doi: 10.1007/978-3-030-16391-4_6. Review.

PMID:
31209845
5.

The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells.

Parasido E, Avetian GS, Naeem A, Graham G, Pishvaian M, Glasgow E, Mudambi S, Lee Y, Ihemelandu C, Choudhry M, Peran I, Banerjee PP, Avantaggiati ML, Bryant K, Baldelli E, Pierobon M, Liotta L, Petricoin E, Fricke ST, Sebastian A, Cozzitorto J, Loots GG, Kumar D, Byers S, Londin E, DiFeo A, Narla G, Winter J, Brody JR, Rodriguez O, Albanese C.

Mol Cancer Res. 2019 Sep;17(9):1815-1827. doi: 10.1158/1541-7786.MCR-19-0191. Epub 2019 Jun 4.

PMID:
31164413
6.

Combination of ERK and autophagy inhibition as a treatment approach for pancreatic cancer.

Bryant KL, Stalnecker CA, Zeitouni D, Klomp JE, Peng S, Tikunov AP, Gunda V, Pierobon M, Waters AM, George SD, Tomar G, Papke B, Hobbs GA, Yan L, Hayes TK, Diehl JN, Goode GD, Chaika NV, Wang Y, Zhang GF, Witkiewicz AK, Knudsen ES, Petricoin EF 3rd, Singh PK, Macdonald JM, Tran NL, Lyssiotis CA, Ying H, Kimmelman AC, Cox AD, Der CJ.

Nat Med. 2019 Apr;25(4):628-640. doi: 10.1038/s41591-019-0368-8. Epub 2019 Mar 4.

7.

Nanonetworks in Biomedical Applications.

Marzo JL, Jornet JM, Pierobon M.

Curr Drug Targets. 2019;20(8):800-807. doi: 10.2174/1389450120666190115152613.

PMID:
30648507
8.

Phosphoprotein-based drug target activation mapping for precision oncology: a view to the future.

Pierobon M, Petricoin EF 3rd, Wulfkuhle JD.

Expert Rev Proteomics. 2018 Nov;15(11):851-853. doi: 10.1080/14789450.2018.1531709. Epub 2018 Oct 12. No abstract available.

PMID:
30301389
9.

An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease.

Younossi ZM, Karrar A, Pierobon M, Birerdinc A, Stepanova M, Abdelatif D, Younoszai Z, Jeffers T, Felix S, Jeiran K, Hodge A, Zhou W, Monge F, Alaparthi L, Chandhoke V, Goodman ZD, Petricoin EF.

BMC Med. 2018 Sep 12;16(1):170. doi: 10.1186/s12916-018-1136-1.

10.

Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma in children: Report from the AIEOP Soft Tissue Sarcoma Committee.

Compostella A, Affinita MC, Casanova M, Milano GM, Scagnellato A, Dall'Igna P, Chiaravalli S, Pierobon M, Manzitti C, Zanetti I, Schiavetti A, Sorbara S, Mura RM, Ruggiero A, Ferrari A, Bisogno G.

Tumori. 2019 Apr;105(2):138-143. doi: 10.1177/0300891618792479. Epub 2018 Aug 22.

PMID:
30131003
11.

Computational Models for Trapping Ebola Virus Using Engineered Bacteria.

Martins DP, Barros MT, Pierobon M, Kandhavelu M, Lio' P, Balasubramaniam S.

IEEE/ACM Trans Comput Biol Bioinform. 2018 Nov-Dec;15(6):2017-2027. doi: 10.1109/TCBB.2018.2836430. Epub 2018 May 15.

PMID:
29994771
12.

Reverse phase protein array (RPPA) combined with computational analysis to unravel relevant prognostic factors in non- small cell lung cancer (NSCLC): a pilot study.

Ludovini V, Chiari R, Tomassoni L, Antonini C, Baldelli E, Baglivo S, Siggillino A, Tofanetti FR, Bellezza G, Hodge KA, Petricoin E, Pierobon M, Crinò L, Bianconi F.

Oncotarget. 2017 Jun 14;8(47):83343-83353. doi: 10.18632/oncotarget.18480. eCollection 2017 Oct 10.

13.

Salvage rates and prognostic factors after relapse in children and adolescents with malignant peripheral nerve sheath tumors.

Bergamaschi L, Bisogno G, Manzitti C, D'Angelo P, Milano GM, Scagnellato A, Cappelletti M, Chiaravalli S, Dall'Igna P, Alaggio R, Ruggiero A, Di Martino M, Affinita MC, Pierobon M, Garaventa A, Casanova M, Ferrari A.

Pediatr Blood Cancer. 2018 Feb;65(2). doi: 10.1002/pbc.26816. Epub 2017 Sep 19.

PMID:
28926683
14.

Exploiting Radiation-Induced Signaling to Increase the Susceptibility of Resistant Cancer Cells to Targeted Drugs: AKT and mTOR Inhibitors as an Example.

Eke I, Makinde AY, Aryankalayil MJ, Sandfort V, Palayoor ST, Rath BH, Liotta L, Pierobon M, Petricoin EF, Brown MF, Stommel JM, Ahmed MM, Coleman CN.

Mol Cancer Ther. 2018 Feb;17(2):355-367. doi: 10.1158/1535-7163.MCT-17-0262. Epub 2017 Aug 11.

15.

Inhibition of AKT1 signaling promotes invasion and metastasis of non-small cell lung cancer cells with K-RAS or EGFR mutations.

Rao G, Pierobon M, Kim IK, Hsu WH, Deng J, Moon YW, Petricoin EF, Zhang YW, Wang Y, Giaccone G.

Sci Rep. 2017 Aug 1;7(1):7066. doi: 10.1038/s41598-017-06128-9.

16.

Winners' Cup: a national football tournament brings together adolescent patients with cancer from all over Italy.

Silva M, Chisari M, Signoroni S, Bassani A, Tagliabue L, Ricci A, Daversa M, Achini M, Spreafico F, Murelli M, Milano GM, Bisogno G, Coccoli L, Conte M, Garaventa A, Indolfi P, Perrotta S, Spinelli M, Mercolini F, Soloni P, Pierobon M, Di Cataldo A, Perillo T, Mascarin M, Coassin E, Veneroni L, Casanova M, Massimino M, Ferrari A.

Tumori. 2017 Jul 31;103(4):e25-e29. doi: 10.5301/tj.5000655.

PMID:
28665473
17.

Kinase-driven metabolic signalling as a predictor of response to carboplatin-paclitaxel adjuvant treatment in advanced ovarian cancers.

Sereni MI, Baldelli E, Gambara G, Ravaggi A, Hodge KA, Alberts DS, Guillen-Rodriguez JM, Dong T, Memo M, Odicino F, Angioli R, Liotta LA, Pecorelli SL, Petricoin EF, Pierobon M.

Br J Cancer. 2017 Aug 8;117(4):494-502. doi: 10.1038/bjc.2017.195. Epub 2017 Jun 29.

18.

Protein network construction using reverse phase protein array data.

Varghese RS, Zuo Y, Zhao Y, Zhang YW, Jablonski SA, Pierobon M, Petricoin EF, Ressom HW, Weiner LM.

Methods. 2017 Jul 15;124:89-99. doi: 10.1016/j.ymeth.2017.06.017. Epub 2017 Jun 24.

19.

Reverse Phase Protein Microarrays.

Baldelli E, Calvert V, Hodge A, VanMeter A, Petricoin EF 3rd, Pierobon M.

Methods Mol Biol. 2017;1606:149-169. doi: 10.1007/978-1-4939-6990-6_11.

PMID:
28502000
20.

Enrichment of PI3K-AKT-mTOR Pathway Activation in Hepatic Metastases from Breast Cancer.

Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, Anthony SP, Robert NJ, Northfelt DW, Jahanzeb M, Vocila L, Wulfkuhle J, Gambara G, Gallagher RI, Dunetz B, Hoke N, Dong T, Craig DW, Cristofanilli M, Leyland-Jones B, Liotta LA, O'Shaughnessy JA, Carpten JD, Petricoin EF.

Clin Cancer Res. 2017 Aug 15;23(16):4919-4928. doi: 10.1158/1078-0432.CCR-16-2656. Epub 2017 Apr 26.

21.

Subthreshold linear modeling of dendritic trees: a computational approach.

Khodaei A, Pierobon M.

Conf Proc IEEE Eng Med Biol Soc. 2016 Aug;2016:235-238. doi: 10.1109/EMBC.2016.7590683.

PMID:
28268320
22.

Protein drug target activation homogeneity in the face of intra-tumor heterogeneity: implications for precision medicine.

Parasido EM, Silvestri A, Canzonieri V, Belluco C, Diodoro MG, Milione M, Melotti F, De Maria R, Liotta L, Petricoin EF, Pierobon M.

Oncotarget. 2017 Jul 25;8(30):48534-48544. doi: 10.18632/oncotarget.14019.

23.

A pilot study exploring the molecular architecture of the tumor microenvironment in human prostate cancer using laser capture microdissection and reverse phase protein microarray.

Pin E, Stratton S, Belluco C, Liotta L, Nagle R, Hodge KA, Deng J, Dong T, Baldelli E, Petricoin E, Pierobon M.

Mol Oncol. 2016 Dec;10(10):1585-1594. doi: 10.1016/j.molonc.2016.09.007. Epub 2016 Oct 14.

24.

Lessons from the Ebola Outbreak: Action Items for Emerging Infectious Disease Preparedness and Response.

Jacobsen KH, Aguirre AA, Bailey CL, Baranova AV, Crooks AT, Croitoru A, Delamater PL, Gupta J, Kehn-Hall K, Narayanan A, Pierobon M, Rowan KE, Schwebach JR, Seshaiyer P, Sklarew DM, Stefanidis A, Agouris P.

Ecohealth. 2016 Mar;13(1):200-12. doi: 10.1007/s10393-016-1100-5. Epub 2016 Feb 25. Review.

PMID:
26915507
25.

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression.

Hayes TK, Neel NF, Hu C, Gautam P, Chenard M, Long B, Aziz M, Kassner M, Bryant KL, Pierobon M, Marayati R, Kher S, George SD, Xu M, Wang-Gillam A, Samatar AA, Maitra A, Wennerberg K, Petricoin EF 3rd, Yin HH, Nelkin B, Cox AD, Yeh JJ, Der CJ.

Cancer Cell. 2016 Jan 11;29(1):75-89. doi: 10.1016/j.ccell.2015.11.011. Epub 2015 Dec 24.

26.

Phosphorylation, Signaling, and Cancer: Targets and Targeting.

Marmiroli S, Fabbro D, Miyata Y, Pierobon M, Ruzzene M.

Biomed Res Int. 2015;2015:601543. doi: 10.1155/2015/601543. Epub 2015 Oct 21. No abstract available.

27.

Functional signaling pathway analysis of lung adenocarcinomas identifies novel therapeutic targets for KRAS mutant tumors.

Baldelli E, Bellezza G, Haura EB, Crinó L, Cress WD, Deng J, Ludovini V, Sidoni A, Schabath MB, Puma F, Vannucci J, Siggillino A, Liotta LA, Petricoin EF 3rd, Pierobon M.

Oncotarget. 2015 Oct 20;6(32):32368-79. doi: 10.18632/oncotarget.5941.

28.

Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Corcoran RB, Atreya CE, Falchook GS, Kwak EL, Ryan DP, Bendell JC, Hamid O, Messersmith WA, Daud A, Kurzrock R, Pierobon M, Sun P, Cunningham E, Little S, Orford K, Motwani M, Bai Y, Patel K, Venook AP, Kopetz S.

J Clin Oncol. 2015 Dec 1;33(34):4023-31. doi: 10.1200/JCO.2015.63.2471. Epub 2015 Sep 21.

29.

Pharmacokinetic Modeling and Biodistribution Estimation Through the Molecular Communication Paradigm.

Chahibi Y, Pierobon M, Akyildiz IF.

IEEE Trans Biomed Eng. 2015 Oct;62(10):2410-20. doi: 10.1109/TBME.2015.2430011. Epub 2015 May 6.

PMID:
25955986
30.

Lung cancer prognosis before and after recurrence in a population-based setting.

Consonni D, Pierobon M, Gail MH, Rubagotti M, Rotunno M, Goldstein A, Goldin L, Lubin J, Wacholder S, Caporaso NE, Bertazzi PA, Tucker MA, Pesatori AC, Landi MT.

J Natl Cancer Inst. 2015 Mar 23;107(6):djv059. doi: 10.1093/jnci/djv059. Print 2015 Jun.

31.

Impact of upfront cellular enrichment by laser capture microdissection on protein and phosphoprotein drug target signaling activation measurements in human lung cancer: Implications for personalized medicine.

Baldelli E, Haura EB, Crinò L, Cress DW, Ludovini V, Schabath MB, Liotta LA, Petricoin EF, Pierobon M.

Proteomics Clin Appl. 2015 Oct;9(9-10):928-37. doi: 10.1002/prca.201400056. Epub 2015 Mar 24.

32.

Functional characterization of epithelial ovarian cancer histotypes by drug target based protein signaling activation mapping: implications for personalized cancer therapy.

Sereni MI, Baldelli E, Gambara G, Deng J, Zanotti L, Bandiera E, Bignotti E, Ragnoli M, Tognon G, Ravaggi A, Meani F, Memo M, Angioli R, Liotta LA, Pecorelli SL, Petricoin E 3rd, Pierobon M.

Proteomics. 2015 Jan;15(2-3):365-73. doi: 10.1002/pmic.201400214.

PMID:
25311472
33.

A pilot study utilizing multi-omic molecular profiling to find potential targets and select individualized treatments for patients with previously treated metastatic breast cancer.

Jameson GS, Petricoin EF, Sachdev J, Liotta LA, Loesch DM, Anthony SP, Chadha MK, Wulfkuhle JD, Gallagher RI, Reeder KA, Pierobon M, Fulk MR, Cantafio NA, Dunetz B, Mikrut WD, Von Hoff DD, Robert NJ.

Breast Cancer Res Treat. 2014 Oct;147(3):579-88. doi: 10.1007/s10549-014-3117-1. Epub 2014 Sep 11.

PMID:
25209003
34.

Pilot phase I/II personalized therapy trial for metastatic colorectal cancer: evaluating the feasibility of protein pathway activation mapping for stratifying patients to therapy with imatinib and panitumumab.

Pierobon M, Silvestri A, Spira A, Reeder A, Pin E, Banks S, Parasido E, Edmiston K, Liotta L, Petricoin E.

J Proteome Res. 2014 Jun 6;13(6):2846-55. doi: 10.1021/pr401267m. Epub 2014 May 14.

PMID:
24787230
35.

Application of molecular technologies for phosphoproteomic analysis of clinical samples.

Pierobon M, Wulfkuhle J, Liotta L, Petricoin E.

Oncogene. 2015 Feb 12;34(7):805-14. doi: 10.1038/onc.2014.16. Epub 2014 Mar 10. Review.

PMID:
24608425
36.

Stratification of clear cell renal cell carcinoma by signaling pathway analysis.

Cremona M, Espina V, Caccia D, Veneroni S, Colecchia M, Pierobon M, Deng J, Mueller C, Procopio G, Lanzi C, Daidone MG, Cho WC, Petricoin EF, Liotta L, Bongarzone I.

Expert Rev Proteomics. 2014 Apr;11(2):237-49. doi: 10.1586/14789450.2014.893193. Epub 2014 Feb 27.

PMID:
24575852
37.

HSP-90 inhibitor ganetespib is synergistic with doxorubicin in small cell lung cancer.

Lai CH, Park KS, Lee DH, Alberobello AT, Raffeld M, Pierobon M, Pin E, Petricoin Iii EF, Wang Y, Giaccone G.

Oncogene. 2014 Oct 2;33(40):4867-76. doi: 10.1038/onc.2013.439. Epub 2013 Oct 28.

38.

A Molecular Communication System Model for Particulate Drug Delivery Systems.

Chahibi Y, Pierobon M, Song SO, Akyildiz IF.

IEEE Trans Biomed Eng. 2013 Dec;60(12):3468-83. doi: 10.1109/TBME.2013.2271503. Epub 2013 Jun 27.

PMID:
23807425
39.

Alcohol consumption and violence among Argentine adolescents.

Pierobon M, Barak M, Hazrati S, Jacobsen KH.

J Pediatr (Rio J). 2013 Jan-Feb;89(1):100-7. doi: 10.1016/j.jped.2013.02.015.

40.

Individualized therapy for metastatic colorectal cancer.

Silvestri A, Pin E, Huijbers A, Pellicani R, Parasido EM, Pierobon M, Petricoin E, Liotta L, Belluco C.

J Intern Med. 2013 Jul;274(1):1-24. doi: 10.1111/joim.12070. Epub 2013 Apr 12. Review.

41.

Reverse phase protein microarrays and their utility in drug development.

Sereni MI, Pierobon M, Angioli R, Petricoin EF 3rd, Frederick MJ.

Methods Mol Biol. 2013;986:187-214. doi: 10.1007/978-1-62703-311-4_13.

PMID:
23436414
42.

Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis.

Pierobon M, Frankenfeld CL.

Breast Cancer Res Treat. 2013 Jan;137(1):307-14. doi: 10.1007/s10549-012-2339-3. Epub 2012 Nov 20. Review.

PMID:
23179600
43.

Protein pathway activation mapping of colorectal metastatic progression reveals metastasis-specific network alterations.

Silvestri A, Calvert V, Belluco C, Lipsky M, De Maria R, Deng J, Colombatti A, De Marchi F, Nitti D, Mammano E, Liotta L, Petricoin E, Pierobon M.

Clin Exp Metastasis. 2013 Mar;30(3):309-16. doi: 10.1007/s10585-012-9538-5. Epub 2012 Sep 29.

44.

Molecular analysis of HER2 signaling in human breast cancer by functional protein pathway activation mapping.

Wulfkuhle JD, Berg D, Wolff C, Langer R, Tran K, Illi J, Espina V, Pierobon M, Deng J, DeMichele A, Walch A, Bronger H, Becker I, Waldhör C, Höfler H, Esserman L; I-SPY 1 TRIAL Investigators, Liotta LA, Becker KF, Petricoin EF 3rd.

Clin Cancer Res. 2012 Dec 1;18(23):6426-35. doi: 10.1158/1078-0432.CCR-12-0452. Epub 2012 Oct 8.

45.

Multiplexed protein signal pathway mapping identifies patients with rectal cancer that responds to neoadjuvant treatment.

Mammano E, Galdi F, Pierobon M, Tessari E, Deng J, Pucciarelli S, Agostini M, De Marchi F, Canzonieri V, De Paoli A, Belluco C, Liotta L, Petricoin E, Pilati P, Nitti D.

Clin Colorectal Cancer. 2012 Dec;11(4):268-74. doi: 10.1016/j.clcc.2012.05.003. Epub 2012 Jun 2.

46.

Microarray data analysis: comparing two population means.

Deng J, Calvert V, Pierobon M.

Methods Mol Biol. 2012;823:325-46. doi: 10.1007/978-1-60327-216-2_21.

PMID:
22081355
47.

Reverse-phase protein microarrays.

Pierobon M, Vanmeter AJ, Moroni N, Galdi F, Petricoin EF 3rd.

Methods Mol Biol. 2012;823:215-35. doi: 10.1007/978-1-60327-216-2_14.

PMID:
22081348
48.

Chemoresistant colorectal cancer cells and cancer stem cells mediate growth and survival of bystander cells.

Bose D, Zimmerman LJ, Pierobon M, Petricoin E, Tozzi F, Parikh A, Fan F, Dallas N, Xia L, Gaur P, Samuel S, Liebler DC, Ellis LM.

Br J Cancer. 2011 Nov 22;105(11):1759-67. doi: 10.1038/bjc.2011.449. Epub 2011 Nov 1.

49.

Reverse phase protein microarrays for clinical applications.

Pierobon M, Belluco C, Liotta LA, Petricoin EF 3rd.

Methods Mol Biol. 2011;785:3-12. doi: 10.1007/978-1-61779-286-1_1.

PMID:
21901589
50.

Mechanism of cell adaptation: when and how do cancer cells develop chemoresistance?

Fodale V, Pierobon M, Liotta L, Petricoin E.

Cancer J. 2011 Mar-Apr;17(2):89-95. doi: 10.1097/PPO.0b013e318212dd3d. Review.

Supplemental Content

Loading ...
Support Center